Charles Schwab Investment Management Inc. Has $28.08 Million Holdings in LivaNova PLC (NASDAQ:LIVN)

Charles Schwab Investment Management Inc. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 606,360 shares of the company’s stock after selling 15,599 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.12% of LivaNova worth $28,081,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LIVN. Point72 Asset Management L.P. grew its stake in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the period. Point72 DIFC Ltd grew its stake in LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after acquiring an additional 181,161 shares during the period. The Manufacturers Life Insurance Company grew its stake in LivaNova by 286.4% in the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after acquiring an additional 153,611 shares during the period. Paradice Investment Management LLC grew its stake in LivaNova by 15.3% in the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company’s stock valued at $22,545,000 after acquiring an additional 64,680 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in LivaNova by 92.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,740 shares of the company’s stock valued at $6,449,000 after acquiring an additional 58,807 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on LIVN. Stifel Nicolaus decreased their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday. Barclays reduced their price objective on LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. Finally, Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Stock Performance

LIVN opened at $41.41 on Tuesday. LivaNova PLC has a 52-week low of $36.85 and a 52-week high of $64.48. The firm has a market capitalization of $2.25 billion, a PE ratio of 98.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The business’s 50-day simple moving average is $45.88 and its 200 day simple moving average is $49.01.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.